Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from West Pharmaceutical Services

5 Set It and Forget It Dividend Aristocrats for a Lifetime of Income

Five Dividend Aristocrats with decades of payout growth offer reliable income, resilient business models, and analyst-backed upside across sectors.

Dividend Aristocrats Offer Safety in Market Storms. Buy These 2 Top-Rated Stocks Now.

Dividend Aristocrats Offer Safety in Market Storms. Buy These 2 Top-Rated Stocks Now.

Dividend Aristocrats bring the calm with steady paychecks, making these two 'Strong Buy'-rated stocks worth a second look here.

These 2 Dividend Aristocrats Are Top Stocks to Buy in Times of Uncertainty

These 2 Dividend Aristocrats Are Top Stocks to Buy in Times of Uncertainty

These companies offer consistent dividend growth and a strong industry presence.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Is West Pharmaceutical Services Stock Underperforming the S&P 500?

West Pharmaceutical Services has lagged behind the broader S&P 500 Index over the past year, but analysts remain highly optimistic about its future growth potential.

3 Top-Rated Dividend Aristocrats to Buy Now for Passive Income

These three companies have increased their dividends for 25-plus years and offer a mix of stability, growth potential, and attractive yields.

Are Wall Street Analysts Predicting West Pharmaceutical Services Stock Will Climb or Sink?

West Pharmaceutical Services has underperformed the broader market over the past year, but Wall Street analysts remain optimistic about the stock’s prospects.

3 Near-oversold Dividend Aristocrats To Buy Before They Pop

These three Dividend Aristocrats trade near oversold levels and offer reliable income and potential capital appreciation.

inkl

Read news from The Economist, FT, and more,
with one subscription

5 Stocks With Rock-Solid Balance Sheets

5 Stocks With Rock-Solid Balance Sheets

As markets get wobbly amid a lack of interest rate clarity, Goldman Sachs has called out these 5 stocks for their industry-leading balance sheet strength.

These Are The 12 Stocks Driving The S&P 500 Higher In 2023

These Are The 12 Stocks Driving The S&P 500 Higher In 2023

The S&P 500 is up 12% so far in 2023, even with the market correction. But an equal-weight ETF is up 0.6%. Nvidia leads the index's big winners.

Investors Business Daily

Organisations

Palo Alto Networks

Arista Networks

Royal Caribbean

Abbott Laboratories

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Topics

inkl

Read news from The Economist, FT, and more,
with one subscription

Places

298,012 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play